Daiichi Sankyo, AZ close on EU approval of Enhertu for breast cancerDaiichi Sankyo and AstraZeneca could be just weeks away from an EU approval for their antibody-drug conjugate (ADC) Share XDaiichi Sankyo, AZ close on EU approval of Enhertu for breast cancerhttps://pharmaphorum.com/news/daiichi-sankyo-az-close-on-eu-approval-of-enhertu-for-breast-cancer/
Roche’s Herceptin/Perjeta combo product nears EU approvalThe EMA’s human medicines committee has recommended approval of a fixed-dose combination of Roche’s breast cancer drugs Herceptin Share XRoche’s Herceptin/Perjeta combo product nears EU approvalhttps://pharmaphorum.com/news/roches-herceptin-perjeta-combo-product-nears-eu-approval/
Kite cues up first EMA okay for mantle cell lymphoma CAR-TGilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for Share XKite cues up first EMA okay for mantle cell lymphoma CAR-Thttps://pharmaphorum.com/news/kite-cues-up-first-ema-okay-for-mantle-cell-lymphoma-car-t/
Novartis’ big bet on inclisiran nears fruition, as CHMP backs drugNovartis’ near-$10 billion takeover of The Medicines Company last year was focused mainly on one asset – cholesterol-lowering Share XNovartis’ big bet on inclisiran nears fruition, as CHMP backs drughttps://pharmaphorum.com/news/novartis-big-bet-on-inclisiran-nears-fruition-as-chmp-backs-drug/
CHMP gives nod to GSK’s BCMA drug Blenrep for myelomaGlaxoSmithKline is closing in on EU approval for its first-in-class BCMA-targeting drug Blenrep, after getting a green light Share XCHMP gives nod to GSK’s BCMA drug Blenrep for myelomahttps://pharmaphorum.com/news/chmp-gives-nod-to-gsks-bcma-drug-blenrep-for-myeloma/
Novartis closes on EU approval for breast cancer drug PiqrayNovartis has moved nearer to claiming approval for its PI3K inhibitor Piqray for breast cancer in the EU, Share XNovartis closes on EU approval for breast cancer drug Piqrayhttps://pharmaphorum.com/news/novartis-closes-on-eu-approval-for-breast-cancer-drug-piqray/
Novartis on point in EU for asthma triple as CHMP backs EnerzairNovartis has moved a step closer to EU approval of its three-drug asthma therapy Enerzair Breezhaler, and now Share XNovartis on point in EU for asthma triple as CHMP backs Enerzairhttps://pharmaphorum.com/news/novartis-on-point-in-eu-for-asthma-triple-as-chmp-backs-enerzair/
CHMP backs safety of anticoagulants after real-world studyThe EMA’s human drugs advisory committee has said that no change is needed to the use of direct Share XCHMP backs safety of anticoagulants after real-world studyhttps://pharmaphorum.com/news/chmp-backs-safety-of-anticoagulants-after-real-world-study/
Novartis closes on EU approval for SMA gene therapy ZolgensmaNovartis is on the final straight to approval of its spinal muscular atrophy (SMA) gene therapy Zolgensma in Share XNovartis closes on EU approval for SMA gene therapy Zolgensmahttps://pharmaphorum.com/news/novartis-closes-on-eu-approval-for-sma-gene-therapy-zolgensma/
